Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease - Varenhorst, C; James, S; Erlinge, D (Eur Heart J, 2009)
et al.